MOTS-C
Evidence: D/EMitochondrial / Cellular Aging
Evidence Snapshot
Regulatory Context
Not FDA-approved. In July 2026, FDA's Pharmacy Compounding Advisory Committee proposed excluding MOTS-c free base and acetate from the 503A Bulks List because of identity, effectiveness, safety, and immunogenicity concerns and the absence of identified human exposure data.
Research Takeaway
MOTS-c is a 16-amino-acid mitochondrial-derived peptide encoded by a short open reading frame within mitochondrial 12S rRNA, with preclinical roles reported in metabolic-stress signaling, AMPK-related pathways, mitonuclear communication, glucose handling, and muscle homeostasis.
See all 6 evidence claims →Quick Summary
MOTS-C is a 16-amino-acid mitochondrial-derived peptide encoded within mitochondrial 12S rRNA, studied for metabolic-stress signaling, AMPK-related pathways, insulin sensitivity, exercise-related biology, and mitonuclear communication. It is not a component of an FDA-approved drug, and in July 2026 FDA proposed excluding MOTS-c free base and acetate from the 503A Bulks List over identity, effectiveness, safety, and immunogenicity concerns. Most therapeutic evidence remains preclinical; it is presented here as experimental, not as a proven human therapy.
Mechanism & Research Overview
MOTS-C is a 16-amino-acid mitochondrial-derived peptide encoded within mitochondrial 12S rRNA, studied for metabolic-stress signaling, AMPK-related pathways, insulin sensitivity, exercise-related biology, and mitonuclear communication. It is not a component of an FDA-approved drug, and in July 2026 FDA proposed excluding MOTS-c free base and acetate from the 503A Bulks List over identity, effectiveness, safety, and immunogenicity concerns. Most therapeutic evidence remains preclinical; it is presented here as experimental, not as a proven human therapy.
Evidence Claims
Individual scientific statements drawn from the sources cited below, each shown with the specific evidence boundary that statement does not establish.
Supported
MOTS-c is a 16-amino-acid mitochondrial-derived peptide encoded by a short open reading frame within mitochondrial 12S rRNA, with preclinical roles reported in metabolic-stress signaling, AMPK-related pathways, mitonuclear communication, glucose handling, and muscle homeostasis.
Sources: MOTS-C discovery/metabolic homeostasis; MOTS-c Nuclear Translocation
Supported
Human research shows that endogenous circulating or skeletal-muscle MOTS-c changes with exercise, age, metabolic state, obesity, and diabetes. A 2021 translational study found that exercise induced endogenous MOTS-c expression in human skeletal muscle and circulation. This does not demonstrate that injecting synthetic MOTS-c reproduces exercise benefits.
Sources: Exercise-Induced Endogenous MOTS-c
Supported
Observational studies report associations between circulating MOTS-c and insulin sensitivity, glucose, HbA1c, obesity, and type 2 diabetes. Associations do not establish causation or treatment efficacy.
Sources: MOTS-c and Insulin Sensitivity
Supported
Under metabolic stress, endogenous MOTS-c can translocate to the nucleus and alter nuclear gene expression, a mechanism reported in preclinical models.
Sources: MOTS-c Nuclear Translocation
Supported
MOTS-c is not a component of an FDA-approved drug. At the July 23-24, 2026 Pharmacy Compounding Advisory Committee meeting, FDA proposed that MOTS-c free base and MOTS-c acetate not be included on the 503A Bulks List, citing inadequate physical/chemical characterization, inconsistent naming and salt/derivative identity, lack of evidence supporting nominated uses, no identified human exposure data, lack of clinical/nonclinical safety information, and unresolved immunogenicity risk. This is a proposal in the 503A review process, not a broader criminal-law or scheduling determination.
Sources: FDA July 2026 PCAC MOTS-c Evaluation
Supported
FDA reported in July 2026 that it had not identified publicly available clinical studies or human-exposure data for drug products containing MOTS-c administered by any route. No controlled human trial establishes that injected synthetic MOTS-c improves insulin sensitivity, exercise capacity, or longevity, and human safety of exogenous MOTS-c remains unknown.
Sources: FDA July 2026 PCAC MOTS-c Evaluation
Safety & Evidence Limitations
Considerations reported in the sources cited on this page — not a complete list of every possible risk, and not medical advice.
Safety Consideration
Human safety and outcome data are limited compared with established medications.Safety Consideration
Mechanistic excitement is largely based on animal, cellular, or early translational research.Safety Consideration
Potential effects on glucose, energy, fatigue, or exercise tolerance are not predictable for individuals.Safety Consideration
Long-term safety, immunogenicity, optimal route, and appropriate population are not established.Safety Consideration
Gray-market products may have identity, purity, sterility, and stability problems.Safety Consideration
FDA reported in July 2026 that it had not identified publicly available clinical studies or human-exposure data for MOTS-c drug products administered by any route; a registered clinical trial (NCT07505745) is designed to test MOTS-c in humans, but a registered or recruiting trial is not evidence of safety or effectiveness.
Research Areas Being Studied
Research areas discussed on this page reflect the Mitochondrial / Cellular Aging category and the sources cited below.
Findings Reported in Studies
Educational summary only — reported in cited studies, not a claim of proven benefit.
- Exercise-Induced Endogenous MOTS-c (2021):
- MOTS-c and Insulin Sensitivity ():
Study Tables by Evidence Type
Human Studies & Clinical Data
| Title | Year | Population / Model | Dose / Duration / Finding | Safety Notes | Source |
|---|---|---|---|---|---|
| Exercise-Induced Endogenous MOTS-c | 2021 | 2021 translational study: exercise induced endogenous MOTS-c expression in human skeletal muscle and circulation. This does not show that injecting synthetic MOTS-c reproduces exercise benefits. | |||
| MOTS-c and Insulin Sensitivity | Observational study reporting associations between circulating MOTS-c and insulin sensitivity, glucose, HbA1c, obesity, and type 2 diabetes. Associations do not establish causation or treatment efficacy. |
Animal / Cell / Preclinical Data
| Title | Year | Population / Model | Dose / Duration / Finding | Safety Notes | Source |
|---|---|---|---|---|---|
| MOTS-C discovery/metabolic homeostasis | 2015 | Animal/mechanistic | Mouse metabolic models — Reported metabolic homeostasis effects and reduced obesity/insulin resistance in models. | Preclinical only; animal/cell findings do not establish human safety or efficacy. | |
| MOTS-c Nuclear Translocation | Under metabolic stress, endogenous MOTS-c can translocate to the nucleus and alter nuclear gene expression. |
Regulatory Documents & Official Trial Registries
| Title | Year | Population / Model | Dose / Duration / Finding | Safety Notes | Source |
|---|---|---|---|---|---|
| FDA July 2026 PCAC MOTS-c Evaluation | 2026 | At the July 23-24, 2026 Pharmacy Compounding Advisory Committee meeting, FDA proposed that MOTS-c free base and MOTS-c acetate not be included on the 503A Bulks List, citing inadequate physical/chemical characterization, inconsistent naming and salt/derivative identity, lack of evidence supporting nominated uses, no identified human exposure data for drug products containing MOTS-c administered by any route, lack of clinical/nonclinical safety information, and unresolved immunogenicity risk. This is a proposal in the 503A review process, not a broader criminal-law or scheduling determination. | |||
| FDA peptide compounding safety page | Current | Regulatory safety context | Compounded peptide substances — States FDA lacks important safety information and human exposure data for compounded MOTS-C. | Official/regulatory context; verify latest label, registry status, and warnings before launch. |
Review Articles / Secondary Sources
| Title | Year | Population / Model | Dose / Duration / Finding | Safety Notes | Source |
|---|---|---|---|---|---|
| MOTS-C promising MDP review | 2023 | Review | Metabolic and aging biology — Describes nuclear regulation and age-related decline discussion. | Secondary source; useful for context but not a substitute for primary study review. | |
| MOTS-C review | 2022 | Review | Mitochondrial-derived peptide biology — Summarizes mechanisms and therapeutic potential in age-related disorders. | Secondary source; useful for context but not a substitute for primary study review. |
Anecdotal Reported Patterns — Not Medical Advice
Anecdotal Reported Patterns — Not Medical Advice
Reported dosing patterns are included for educational context only. They are self-reported, unverified, not medical advice, and not instructions for human use. Community-submitted patterns are not yet available in this Phase 1 prototype; this section is a placeholder reserved for moderated, aggregated community data.
Lab Markers to Discuss With a Clinician
Educational topics only — not self-monitoring instructions.
FAQ
Disclaimer
MOTS-C is experimental in the contexts discussed on this page. Nothing here implies an established human treatment benefit or confirms safety for human use.
Educational use only. This content is provided for informational and research-summary purposes only. It is not medical advice, not a treatment recommendation, not a dosing guide, and not a substitute for care from a licensed medical professional. Nothing here is intended to diagnose, treat, cure, prevent, or mitigate disease. Reported dosing patterns, when shown elsewhere on the site, must be labeled either as Study / Trial Dosing or Anecdotal Reported Patterns — Not Medical Advice. Community reports are self-reported, unverified, and not scientific proof.
Community-reported experiences, once enabled, must be displayed only as moderated, anonymized, or aggregated data. They are anecdotal, self-reported, unverified, and should never be presented as proof of safety, efficacy, or expected results.
Content status: Website/CMS content draft; source verification and legal/privacy review required before public launch. Last updated 2026-07-08.
Follow research updates for MOTS-C
Get notified in your MitoCore account when this profile is updated, a new study is added, or its evidence grade changes.
Get updates when new studies or safety notes are added for this peptide.
Get educational updates on new studies, evidence-grade changes, and safety notes. Educational content only — not medical advice.